From Surf Wiki (app.surf) — the open knowledge base
ACP-105
| Column 1 |
|---|
| .mw-parser-output .plainlist ol,.mw-parser-output .plainlist ul{line-height:inherit;list-style:none;margin:0;padding:0}.mw-parser-output .plainlist ol li,.mw-parser-output .plainlist ul li{margin-bottom:0} |
| US: Investigational new drug |
| IUPAC name |
| 2-chloro-4-(3-hydroxy-3-methyl-8-azabicyclo[3.2.1]octan-8-yl)-3-methylbenzonitrile |
| 1048998-11-3 |
| 11507567 |
| 9682364 |
| ChEMBL3410856 |
| DTXSID101134942 |
| C16H19ClN2O |
| 290.79 g·mol−1 |
| Interactive image |
| SMILES |
| CC1=C(C=CC(=C1Cl)C#N)N2C3CCC2CC(C3)(C)O |
| InChI |
| InChI=1S/C16H19ClN2O/c1-10-14(6-3-11(9-18)15(10)17)19-12-4-5-13(19)8-16(2,20)7-12/h3,6,12-13,20H,4-5,7-8H2,1-2H3Key:OUEODVPKPRQETQ-UHFFFAOYSA-N |
ACP-105 is a drug which acts as a selective androgen receptor modulator (SARM). It has been investigated for potential use in the treatment of age-related cognitive decline. The drug has been found to reduce anxiety-like behavior in a mouse model of Alzheimer's disease when administered alone, as well as enhance spatial memory when coadministered with the selective estrogen receptor β agonist AC-186. ACP-105 is an aniline SARM and is related to AC-262536 and vosilasarm (RAD140).
Ask Mako anything about ACP-105 — get instant answers, deeper analysis, and related topics.
Research with MakoFree with your Surf account
Create a free account to save articles, ask Mako questions, and organize your research.
Sign up freeThis content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.
Report